These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 21051648)

  • 1. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
    Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
    J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
    Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
    Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
    Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
    J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.
    Yap KK; Yap KS; Byrne AJ; Berlangieri SU; Poon A; Mitchell P; Knight SR; Clarke PC; Harris A; Tauro A; Rowe CC; Scott AM
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1033-40. PubMed ID: 15875178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
    Wang YT; Huang G
    Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
    Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
    Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.
    Alzahouri K; Lejeune C; Woronoff-Lemsi MC; Arveux P; Guillemin F
    Clin Radiol; 2005 Apr; 60(4):479-92. PubMed ID: 15767106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
    Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA;
    Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
    Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
    Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
    Scott WJ; Shepherd J; Gambhir SS
    Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Staging non-small lung cancer with positron emission tomography: diagnostic value, impact on patient management, and cost-effectiveness.
    Nosotti M; Castellani M; Longari V; Chella B; Baisi A; Rosso L; Santambrogio L
    Int Surg; 2008; 93(5):278-83. PubMed ID: 19943430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging.
    Antoch G; Stattaus J; Nemat AT; Marnitz S; Beyer T; Kuehl H; Bockisch A; Debatin JF; Freudenberg LS
    Radiology; 2003 Nov; 229(2):526-33. PubMed ID: 14512512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer.
    Esnaola NF; Lazarides SN; Mentzer SJ; Kuntz KM
    J Clin Oncol; 2002 Jan; 20(1):263-73. PubMed ID: 11773178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion.
    Halpern BS; Schiepers C; Weber WA; Crawford TL; Fueger BJ; Phelps ME; Czernin J
    Chest; 2005 Oct; 128(4):2289-97. PubMed ID: 16236886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial.
    Søgaard R; Fischer BM; Mortensen J; Højgaard L; Lassen U
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):802-9. PubMed ID: 21210111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
    Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S
    Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in positron emission tomography technology have increased the need for surgical staging in non-small cell lung cancer.
    Lee BE; von Haag D; Lown T; Lau D; Calhoun R; Follette D
    J Thorac Cardiovasc Surg; 2007 Mar; 133(3):746-52. PubMed ID: 17320577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy.
    Gugiatti A; Grimaldi A; Rossetti C; Lucignani G; De Marchis D; Borgonovi E; Fazio F
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):49-61. PubMed ID: 15195004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
    Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
    Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.